News und Analysen
For First Time, Humana Offering Medicare Advantage Plans in Connecticut
Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding health plan choices for Medicare beneficiaries in Connecticut by offering affordable Humana Medicare Advantage plans in
Ipsen erweitert seine präklinische Forschungs- und Entwicklungspipeline für Onkologie im Rahmen einer exklusiven weltweiten Zusammenarbeit mit Accent Therapeutics um ein weiteres Programm mit Fokus auf das RNA-modifizierende Protein METTL3
Haftungsausschluss: Nur für internationale Medien und Investoren bestimmt
Ipsen (Euronext: IPN; ADR: IPSEY) und Accent Therapeutics (Accent) haben eine exklusive weltweite
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3
Regulatory News:
Disclaimer: Intended for international media and investor audiences only
Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive
Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the 100 mg and
Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer
Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of
Dexcom Expands Time in Range Initiative with Nick Jonas to Help Improve the Lives of People with Diabetes in the UK
DexCom, Inc. (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, today announced the UK launch of its Time in Range Campaign, an awareness and education
Humana Continues Extensive Statewide Expansion in Tennessee
Leading health and well-being company Humana Inc. (NYSE: HUM) today announced another major expansion of its Medicare Advantage (MA) offerings across Tennessee for the 2022 plan year. It’s part of
Quidel Announces Preliminary Revenue for Fiscal Third Quarter 2021
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today preliminary results
Humana Expands Access to Affordable Medicare Options in Eastern North Carolina
Leading health and well-being company Humana Inc. (NYSE: HUM) announced today it is introducing a new affordable, whole person health care Medicare Advantage PPO plan in rural communities located
PerkinElmer Receives FDA Emergency Use Authorization for Respiratory SARS-CoV-2 Panel
PerkinElmer, Inc. (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1
Humana Foundation Donates $200,000 to Recovery Efforts for Louisianans Impacted by Hurricane Ida
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is donating $200,000 to the recovery and relocation efforts for those impacted by Hurricane Ida in
Waters Corporation Appoints John M. Ballbach to Board of Directors
Waters Corporation (NYSE:WAT) today announced the appointment of John M. Ballbach to its Board of Directors, effective October 5, 2021. Mr. Ballbach currently serves on the Board of RPM
Louisville Nonprofits Awarded $1.8 Million Through the Humana Foundation’s Community Partners Program
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is awarding $1.8 million to several nonprofit organizations in Louisville as part of its ongoing Community
Dexcom Schedules Third Quarter 2021 Earnings Release and Conference Call for October 28, 2021 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2021 financial results after market close on Thursday, October 28, 2021. Management will hold a conference call
Humana Expanding Medicare Advantage Health Plans in 2022 to Address Beneficiaries’ Most Important Needs, Delivering Predictable, Affordable and Understandable Health Care
Humana Inc. (NYSE: HUM) today announced details of its 2022 Medicare product offerings, including many Medicare Advantage and Prescription Drug Plans that are built to address the needs of diverse
Japan’s MHLW Approves Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released
Pfizer Inc. (NYSE:PFE) today announced positive top-line results from a Phase 3 study (B7471004) evaluating the safety and immunogenicity of PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine)
Dexcom G6 Continuous Glucose Monitoring System Now Covered in Manitoba for Young People With Type 1 Diabetes
Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (CGM), is happy to share that people with type 1 diabetes who are 25 years of age or under may now be
The University of Mississippi Medical Center and Humana Sign Agreement, Expanding Humana’s Medicare Advantage Provider Network in Jackson, Lexington and Grenada
The University of Mississippi Medical Center (UMMC), Mississippi’s only academic health science center, and Humana, a leading health and well-being company, have signed an in-network agreement
Agilent Announces Thought Leader Award to Bernhard Lendl at the TU Wien (Vienna)
Agilent Technologies Inc. (NYSE: A) today announced Professor Bernhard Lendl has been selected to receive a prestigious Agilent Thought Leader Award. Highly renowned in the field of vibrational
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they have submitted data to the U.S. Food and Drug Administration (FDA) from the Phase 2/3 trial of their COVID-19 vaccine in
Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program
Pfizer Inc. (NYSE: PFE) announced today that the first participants have been dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of a single dose
Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults
Pfizer Inc. (NYSE: PFE) today announced the start of the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study to evaluate the investigational novel
Dr. Mikael Dolsten Named to Agilent Board of Directors
Agilent Technologies, Inc. (NYSE: A) today announced that Dr. Mikael Dolsten, chief scientific officer and president, Worldwide Research, Development and Medical, Pfizer Inc. has been elected to
Humana and Kelsey-Seybold Clinic Team up to Expand Access to Value-based Care, Broadening Humana’s Medicare Advantage Provider Network in the Greater Houston Area
Humana, a leading health and well-being company, and Kelsey-Seybold Clinic have signed an in-network agreement, expanding access to care to include members of Humana Medicare Advantage HMO plans.